"From the in-licensing/acquisition perspective, this panel will assess the opportunities and what that can be learned from new deals, including portfolio review; integration of projects in an entrepreneurial environment; how to retain talent
and know-how; building new cultures, vision and values; leveraging organizational structures; acquisition of one partner in established partnerships; and valuation gaps between in-licensing and acquisitions. This session will also assess how a small/midsize biotech can best position itself to make acquisition an attractive option. The acquisition of Serono S.A. by Merck KGaA will be one of the examples discussed."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.